Abstract
Evaluation of: Robinson JD, Lam CY, Minnix JA et al.: The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. (2006) (Epub ahead of print). An increasing number of studies have investigated the role of genetic factors in smoking cessation, and in response to smoking cessation pharmacotherapy. Robinson and colleagues report data on the effects of the dopamine D2 receptor gene Taq1B polymorphism on smoking cessation and withdrawal. While the results add to the growing literature on smoking cessation pharmacogenetics, they also illustrate that minor differences in phenotype definition may influence the results of pharmacogenetic analyses. Existing studies also lack direct comparability, which makes it difficult to judge evidence for replication. Several future directions for smoking cessation pharmacogenetics research are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
